251 related articles for article (PubMed ID: 28148938)
1. 2016 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2017 Feb; 16(2):73-76. PubMed ID: 28148938
[No Abstract] [Full Text] [Related]
2. Market watch: Value of 2016 FDA drug approvals: reversion to the mean?
Schulze U; Ringel M; Panier V; Baedeker M
Nat Rev Drug Discov; 2017 Feb; 16(2):78. PubMed ID: 28148943
[No Abstract] [Full Text] [Related]
3. The Food and Drug Administration perspective: use of an investigational drug in a medical emergency.
Schultheis LW; Rappaport BA
Anesth Analg; 2007 Mar; 104(3):479-80. PubMed ID: 17312189
[No Abstract] [Full Text] [Related]
4. Significant FDA approvals in 1997.
Rheinstein PH; Akbari B
Am Fam Physician; 1998 Jun; 57(11):2865-8. PubMed ID: 9636343
[No Abstract] [Full Text] [Related]
5. New drug awaiting FDA approval may reverse bone loss.
Mayo Clin Health Lett; 2001 Nov; 19(11):4. PubMed ID: 11692627
[No Abstract] [Full Text] [Related]
6. Breakthrough-Therapy Designation - An FDA Perspective.
Corrigan-Curay J; McKee AE; Stein P
N Engl J Med; 2018 Apr; 378(15):1457-1458. PubMed ID: 29641963
[No Abstract] [Full Text] [Related]
7. FDA approves AIDS drug.
Am Pharm; 1992 Sep; NS32(9):13-4. PubMed ID: 1332462
[No Abstract] [Full Text] [Related]
8. FDA approves splice-modulating drug.
Mullard A
Nat Rev Drug Discov; 2017 Feb; 16(2):77. PubMed ID: 28148945
[No Abstract] [Full Text] [Related]
9. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
10. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
11. Regulatory watch: FDA guidance on co-developing investigational drugs.
Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094
[No Abstract] [Full Text] [Related]
12. New FDA breakthrough-drug category--implications for patients.
Darrow JJ; Avorn J; Kesselheim AS
N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173
[No Abstract] [Full Text] [Related]
13. 2013 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2014 Feb; 13(2):85-9. PubMed ID: 24481294
[No Abstract] [Full Text] [Related]
14. FDA plans to continue cracking down on unapproved drugs.
Lavine G
Am J Health Syst Pharm; 2008 Sep; 65(17):1594. PubMed ID: 18714097
[No Abstract] [Full Text] [Related]
15. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
16. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
17. FDA approves treatment IND protocol for taxol.
Clin Pharm; 1992 Nov; 11(11):912. PubMed ID: 1361164
[No Abstract] [Full Text] [Related]
18. EU law mandates drug testing in children.
Sinha G
J Natl Cancer Inst; 2008 Jan; 100(2):84-5. PubMed ID: 18182609
[No Abstract] [Full Text] [Related]
19. 2007 FDA drug approvals: a year of flux.
Hughes B
Nat Rev Drug Discov; 2008 Feb; 7(2):107-9. PubMed ID: 18246607
[No Abstract] [Full Text] [Related]
20. FDA allows second experimental drug to be tested in Ebola patients.
McCarthy M
BMJ; 2014 Aug; 349():g5103. PubMed ID: 25113141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
